Probiotic peanut oral immunotherapy is associated with long-term persistence of 8-week sustained unresponsiveness and long-lasting quality-of-life improvement

dc.check.date2023-04-29
dc.check.infoAccess to this article is restricted until 12 months after publication by request of the publisher.en
dc.contributor.authorLoke, Paxton
dc.contributor.authorHsiao, Kuang-Chih
dc.contributor.authorChebar Lozinsky, Adriana
dc.contributor.authorAshley, Sarah E.
dc.contributor.authorLloyd, Melanie
dc.contributor.authorPitkin, Sigrid
dc.contributor.authorAxelrad, Christine Jean
dc.contributor.authorJayawardana, Kaushala S.
dc.contributor.authorTey, Dean
dc.contributor.authorSu, Ee Lyn
dc.contributor.authorRobinson, Marnie
dc.contributor.authorLeung, Agnes Sy
dc.contributor.authorDunn Galvin, Audrey
dc.contributor.authorTang, Mimi LK
dc.contributor.funderMurdoch Children’s Research Institute, Australiaen
dc.contributor.funderAustralian Food Allergy Foundationen
dc.contributor.funderState Government of Victoriaen
dc.contributor.funderAustralian Governmenten
dc.contributor.funderRoyal Australasian College of Physiciansen
dc.date.accessioned2022-05-05T11:17:14Z
dc.date.available2022-05-05T11:17:14Z
dc.date.issued2022-04-29
dc.date.updated2022-05-04T15:47:21Z
dc.descriptionResearch Letteren
dc.description.abstractThere are few data on long-term effects and quality of life impact of peanut OIT. PPOIT was shown to induce 8-week sustained unresponsiveness that persists to 3-years post-treatment after ad libitum peanut ingestion. PPOIT provides lasting benefits for children with peanut allergy, with long-lasting improvement in health-related quality of life.en
dc.description.sponsorshipState Government of Victoria (Operational Infrastructure Support Program); Australian Government (Research Training Scholarship); Murdoch Children’s Research Institute (Postgraduate Research Scholarship); Royal Australasian College of Physicians (Fellows Research Scholarship)en
dc.description.statusPeer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationLoke, P., Hsiao, K.-C., Chebar Lozinsky, A., Ashley, S. E., Lloyd, M., Pitkin, S., Axelrad, C. J., Jayawardana, K. S., Tey, D., Su, E. L., Robinson, M., Leung, A. S., Dunn Galvin, A. and Tang, M. L. K. (2022) 'Probiotic peanut oral immunotherapy is associated with long-term persistence of 8-week sustained unresponsiveness and long-lasting quality-of-life improvement', Clinical and Experimental Allergy. doi: 10.1111/cea.14137en
dc.identifier.doi10.1111/cea.14137en
dc.identifier.eissn1365-2222
dc.identifier.issn0954-7894
dc.identifier.journaltitleClinical and Experimental Allergyen
dc.identifier.urihttps://hdl.handle.net/10468/13145
dc.language.isoenen
dc.publisherJohn Wiley & Sons, Inc.en
dc.rights© 2022, John Wiley & Sons, Ltd. This is the peer reviewed version of the following article: Loke, P., Hsiao, K.-C., Chebar Lozinsky, A., Ashley, S. E., Lloyd, M., Pitkin, S., Axelrad, C. J., Jayawardana, K. S., Tey, D., Su, E. L., Robinson, M., Leung, A. S., Dunn Galvin, A. and Tang, M. L. K. (2022) 'Probiotic peanut oral immunotherapy is associated with long-term persistence of 8-week sustained unresponsiveness and long-lasting quality-of-life improvement', Clinical and Experimental Allergy, doi: 10.1111/cea.14137, which has been published in final form at: https://doi.org/10.1111/cea.14137. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.en
dc.subjectPeanut allergyen
dc.subjectHealth-related quality of lifeen
dc.subjectOral immunotherapyen
dc.subjectProbioticen
dc.subjectSustained unresponsivenessen
dc.titleProbiotic peanut oral immunotherapy is associated with long-term persistence of 8-week sustained unresponsiveness and long-lasting quality-of-life improvementen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Clin_Experimental_Allergy_-_2022_-_Loke_-_Probiotic_peanut_oral_immunotherapy_is_associated_with_long‐term_persistence_of_(1).pdf
Size:
6.27 MB
Format:
Adobe Portable Document Format
Description:
Accepted Version
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description: